FDA Oks leukemia drug

FEB 12, 2014 – FDA RELEASE – As part of its accelerated approval process the FDA approved ibrutinib (Imbruvica) as a second-line therapy for people whose chronic lymphocytic leukemia (CLL) has relapsed or did not respond to standard therapy. The approval is based on a 48-patient clinical trial that tested whether or not tumors responded to the drug. Whether the drug improves survival or provides other benefits has not been determined.

Read more >>